MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK company's shareholders. Investors in Verona – a specialist in ...

Diesel rally sparked by Western sanctions on Russia will be short-lived A new wave of Western sanctions on Russia’s oil industry has roiled the diesel market, sending refining margins soaring, but ...

Green hydrogen emits only water vapor when burned. Investing in hydrogen stocks offers high growth potential but faces obstacles from high production costs and market volatility. Leading companies ...

Modern single-bedroom apartment in prime location with secure parking & swimming pool. Phone enquiries - please quote property ID 38115. Perfectly positioned on the second floor of the peaceful ...